LPS-induced mouse mastitis is one of the most widely used preclinical models for studying mammary gland inflammation and screening anti-mastitis therapeutic candidates. Dose determination testing establishes the optimal lipopolysaccharide challenge level that produces reproducible, moderate-to-severe inflammation without unacceptable systemic toxicity or mortality. This article outlines the technical principles, sample types, testing items, experimental methods, and applications of dose optimization studies for LPS-induced mastitis in mice.
Technical Overview
Mastitis is the inflammation of mammary gland tissue, most commonly caused by bacterial infection, and represents a significant burden in both dairy production and lactating women. Among experimental models, the lipopolysaccharide (LPS)-induced mouse mastitis model is the standard approach for reproducing acute Gram-negative bacterial mastitis in a controlled laboratory setting. LPS, an endotoxin derived from the outer membrane of Gram-negative bacteria such as E. coli, activates the TLR4/MD-2 receptor complex on mammary epithelial cells and immune cells, triggering downstream NF-κB and MAPK signaling cascades, inflammasome activation, and a robust release of pro-inflammatory mediators.
In the model, LPS is delivered directly into the mammary gland through the teat canal (intramammary injection), typically targeting the fourth pair of abdominal glands. The resulting pathology closely mimics clinical acute mastitis: neutrophil infiltration, alveolar disruption, edema, elevated cytokines, and oxidative stress. However, the biological outcome is highly dose-dependent. Sub-threshold doses produce inconsistent, weak inflammation that fails to provide a detectable therapeutic window, while excessive doses induce systemic endotoxemia, septic shock, and mortality. Dose determination testing is therefore the foundational step in model establishment, involving a structured dose-escalation pilot study followed by multi-endpoint validation.
Commonly reported effective dose ranges in the literature span approximately 10 to 100 μg LPS per gland, with 25–50 μg per gland dissolved in 25–50 μL sterile PBS being the most frequently used regimen for strains such as C57BL/6, BALB/c, and ICR (CD-1) mice. All procedures must be conducted under approved institutional animal care protocols, following the principles of the 3Rs (replacement, reduction, refinement), the ARRIVE reporting guidelines, and applicable national laboratory animal standards such as GB 14925.
Testing Samples
Mammary Gland Tissue
The challenged abdominal (#4) mammary glands are collected at defined terminal time points. Tissue is divided for multiple analyses: one portion fixed in 4% paraformaldehyde for histopathological sectioning and H&E staining, one portion snap-frozen in liquid nitrogen for protein extraction (western blotting, ELISA of tissue homogenates), and one portion used fresh for myeloperoxidase (MPO) activity assays. Contralateral or sham-infused glands serve as internal controls.
Blood, Serum, and Plasma
Peripheral blood is collected via the tail vein at serial time points or by cardiac puncture at necropsy. Serum is used for quantification of circulating cytokines (TNF-α, IL-1β, IL-6), liver and kidney function markers to assess systemic toxicity, and endotoxin translocation indicators. Whole blood supports complete blood count analysis, including total leukocyte and neutrophil differential counts.
Tissue Homogenates and Lavage Fluid
Prepared mammary homogenates are assayed for inflammatory cytokine content normalized to total protein (BCA method), oxidative stress markers, and MPO activity. Where applicable, mammary ductal lavage fluid can provide local inflammatory cell profiles.
Testing Items
Dose determination studies are evaluated across integrated endpoint categories:
- Histopathological inflammation scoring: blinded H&E-based grading of neutrophil infiltration, alveolar and acinar damage, edema, and necrosis, typically on a 0–4 or 0–5 semi-quantitative scale.
- MPO activity: a quantitative marker of neutrophil sequestration within the mammary tissue.
- Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, and IL-8/KC measured by ELISA in serum and tissue homogenates.
- Signaling pathway proteins: TLR4, MyD88, phosphorylated and total NF-κB p65, IκBα degradation, and NLRP3 inflammasome components (NLRP3, ASC, cleaved caspase-1) by western blot.
- Oxidative stress markers: malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH), glutathione peroxidase (GSH-Px), and catalase (CAT).
- Hematological and clinical indicators: total and differential leukocyte counts, body weight change, rectal temperature, general clinical scores, and survival rate.
- Gross pathology: mammary gland wet weight and organ index, hemorrhage, and edema assessment.
Testing Methods
Dose-Escalation Pilot Design
A typical dose-finding study uses 4–6 dose levels (for example, 0, 10, 25, 50, and 100 μg LPS per gland) with 6–10 female mice per group, including a sham group receiving sterile PBS vehicle only. A commonly used LPS source is E. coli serotype O55:B5 or O111:B4, reconstituted in endotoxin-free sterile PBS and delivered in a fixed 25–50 μL infusion volume. The study identifies the dose producing consistent moderate inflammation with mortality below the pre-specified threshold (commonly <10%).
Intramammary Administration Procedure
Mice (commonly 8–10 week old females; lactating dams on days 7–10 post-partum or nulliparous females depending on study design) are anesthetized with an approved regimen such as isoflurane inhalation or pentobarbital sodium. The teat of the fourth abdominal mammary gland is visualized under a dissecting microscope or magnifier, and a fine Hamilton syringe fitted with a blunt 30–33G needle is inserted gently into the teat canal. The LPS solution is infused slowly to avoid canal damage or retrograde leakage. Analgesia and thermal support are provided during recovery.
Observation and Sampling Schedule
Clinical signs, body weight, and temperature are recorded at baseline and at defined intervals. The peak inflammatory response in this model typically occurs at approximately 24 hours post-induction, so terminal sampling is commonly performed at 24 h, with optional time-course arms at 6 h, 12 h, and 48 h to characterize kinetic profiles. Blood and mammary tissues are harvested under deep anesthesia, processed as described above, and analyzed in a blinded fashion where scoring is involved.
Acceptance Criteria for Dose Selection
The selected induction dose must demonstrate: (1) statistically significant elevation of TNF-α, IL-1β, and IL-6 relative to sham controls; (2) histopathological inflammation scores of at least moderate severity with good intra-group reproducibility (coefficient of variation typically <30%); (3) clear MPO activity increase; and (4) acceptable tolerability, defined as mortality below threshold and body weight loss within humane endpoints. Dose–response curves fitted to cytokine and histology data support selection of the minimal effective dose with maximal reproducibility.
Quality Assurance
Reagent lot verification, endotoxin activity confirmation of the LPS working solution, randomized group allocation, blinded outcome assessment, and verification of uniform infusion technique are essential quality controls. Histopathology scoring should be performed by two independent, blinded observers with inter-rater agreement verification. Studies are typically conducted in accredited third-party laboratories or institutional core facilities compliant with ISO/IEC 17025-aligned quality management systems and AAALAC-consistent animal care practices.
Applications
- Anti-mastitis drug screening: evaluating small molecules, biologics, and antibiotics for therapeutic or adjunctive efficacy against acute bacterial mastitis.
- Phytochemical and nutraceutical research: preclinical validation of plant extracts, flavonoids, alkaloids, and functional food ingredients with anti-inflammatory properties.
- Mechanistic studies: dissecting the TLR4/NF-κB, MAPK, and NLRP3/caspase-1/GSDMD signaling axes in mammary inflammation using knockout or pharmacologically inhibited animals.
- Oxidative stress research: investigating the interplay between endotoxin challenge and antioxidant defense pathways in mammary tissue.
- Antimicrobial resistance research: testing anti-virulence and anti-endotoxin strategies that target the host inflammatory response rather than bacterial viability.
- Dairy science and lactation biology: translational studies on bovine mastitis biology and mammary gland innate immunity.
- Biomarker discovery: identifying circulating and tissue biomarkers of mammary inflammation severity and treatment response.
FAQ
Q1: What is the optimal LPS dose for inducing mastitis in mice?
Most published protocols use 25–50 μg LPS per gland in 25–50 μL PBS for C57BL/6, BALB/c, or ICR mice, harvested at 24 hours. However, the optimal dose is strain-, age-, preparation-, and facility-dependent, which is precisely why a formal dose determination study with local validation is recommended before efficacy testing.
Q2: Which LPS serotype is preferred?
E. coli O55:B5 and O111:B4 are the most commonly used serotypes for intramammary induction. The same serotype and supplier formulation should be maintained throughout a research program, as endotoxin activity varies between preparations.
Q3: Should lactating or nulliparous mice be used?
Lactating dams (days 7–10 post-partum) develop more pronounced inflammation due to active milk secretion and ductal patency, offering higher sensitivity. Nulliparous females are technically easier to handle and avoid pup-related variables. The choice should match the research question and be fixed during dose optimization.
Q4: Why is the 24-hour time point most frequently used?
Neutrophil infiltration, cytokine expression, and histological damage peak around 18–24 hours after intramammary LPS challenge and begin to plateau or partially resolve thereafter. Time-course pilot arms are recommended when kinetic characterization is required.
Q5: How is a successful induction confirmed?
Confirmation requires convergent evidence: significant elevation of pro-inflammatory cytokines, increased MPO activity, histologically confirmed neutrophilic infiltration and alveolar damage, and elevated mammary gland index, all relative to sham controls.
Q6: What ethical considerations apply?
All work must be reviewed and approved by the institutional animal care and use committee, incorporate humane endpoints (weight loss limits, severe lethargy, hypothermia), provide appropriate anesthesia and analgesia, and use the minimum number of animals consistent with statistical power, in line with the 3Rs principle and ARRIVE reporting standards.